Darlene Brunzell named program leader of Cancer Prevention and Control
Darlene Brunzell, Ph.D., has been appointed the co-leader of the Cancer Prevention and Control (CPC) research program at VCU Massey Cancer Center. She will serve in this capacity alongside Jennifer Elston Lafata, Ph.D., who has co-led the program since 2010.
Massey researchers awarded grant to study the impact of e-cigarette advertising on youth
VCU Massey Cancer Center researchers Andrew Barnes, Ph.D., and Caroline Cobb, Ph.D., were recently awarded a $450,000 grant from the Virginia Foundation for Healthy Youth (VFHY) to study the impact of electronic cigarette advertising on youth ages 13-18. The results of the study will help inform policy makers as they determine whether the marketing of e-cigarettes should be regulated in the same fashion as their combustible cigarette counterparts.
Massey researcher awarded nearly $1 million to develop a clinical trial to test a new AML therapy
VCU Massey Cancer Center researcher Steven Grant, M.D., was awarded nearly $1 million in grant funding from the National Center for Advancing Translational Sciences (NCATS) to support the development of a clinical trial that will test a novel, experimental therapy for acute myeloid leukemia (AML, an aggressive blood cancer) that he co-discovered.
Massey researchers recognized with VCU distinguished faculty awards
VCU Massey Cancer Center’s director, Gordon Ginder, M.D., and Massey researcher, Thomas Eissenberg, Ph.D., were recognized with prestigious awards at Virginia Commonwealth University’s 2015 Opening Faculty Address and Convocation on Tuesday, August 18. Awards were presented to faculty members who have distinguished themselves and the university through their commitment to excellence, service, teaching and scholarship.
Massey researcher receives grant funding to support further pre-clinical testing of a promising neuroblastoma therapy
VCU Massey Cancer Center researcher Anthony Faber, Ph.D., was awarded a $250,000 grant from Alex’s Lemonade Stand Foundation to support further laboratory research to provide the validation needed to develop clinical trials to test a new therapy for neuroblastoma, the second deadliest cancer in children.